Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Hls Therapeutics Inc (HLS.TO)
Hls Therapeutics Inc (HLS.TO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 110,323
  • Shares Outstanding, K 32,071
  • Annual Sales, $ 61,467 K
  • Annual Income, $ -23,598 K
  • 60-Month Beta 1.14
  • Price/Sales 1.30
  • Price/Cash Flow 5.27
  • Price/Book 0.80
Trade HLS.TO with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/23
See More
  • Average Estimate -0.13
  • Number of Estimates 2
  • High Estimate -0.08
  • Low Estimate -0.18
  • Prior Year -0.27
  • Growth Rate Est. (year over year) +51.85%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.34 +2.99%
on 11/27/23
5.02 -31.47%
on 11/03/23
-1.49 (-30.22%)
since 11/01/23
3-Month
3.34 +2.99%
on 11/27/23
5.52 -37.68%
on 09/13/23
-1.23 (-26.34%)
since 09/01/23
52-Week
3.34 +2.99%
on 11/27/23
11.22 -69.34%
on 12/14/22
-6.51 (-65.43%)
since 12/01/22

Most Recent Stories

More News
New REDUCE-IT® Analyses Show Vascepa® (Icosapent Ethyl) Associated with 29 Percent Relative Risk Reduction Compared with Placebo in Prespecified Subgroup of Patients with Metabolic Syndrome, but Without Diabetes at Baseline

/CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focused on addressing unmet needs in the treatment of psychiatric...

HLS.TO : 3.44 (-1.43%)
HLS Therapeutics Announces Q3 Fiscal 2023 Financial Results and Renewal of Normal Course Issuer Bid

/CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focused on addressing unmet needs in the treatment of psychiatric...

PFE : 28.91 (-5.12%)
HLS.TO : 3.44 (-1.43%)
HLS Therapeutics to Host Q3 Fiscal 2023 Financial Results Conference Call

/CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), announces that it will release its Q3 Fiscal 2023 financial results on Thursday, November 9,...

HLS.TO : 3.44 (-1.43%)
Stocks in play: HLS Therapeutics Inc.

Announces that CEO Craig Millian will present at H.C. Wainwright's 25th Annual Global Investment Conference, ...

HLS.TO : 3.44 (-1.43%)
HLS Therapeutics to Present at H.C. Wainwright's 25th Annual Global Investment Conference

/CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focusing on central nervous system ("CNS") and cardiovascular...

HLS.TO : 3.44 (-1.43%)
HLS Therapeutics Announces Updates to its Credit Agreement

/CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focusing on central nervous system and cardiovascular markets,...

JPM : 156.84 (+0.49%)
HLS.TO : 3.44 (-1.43%)
HLS Therapeutics Announces Q2 Fiscal 2023 Financial Results

/CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focusing on central nervous system ("CNS") and cardiovascular...

HLS.TO : 3.44 (-1.43%)
HLS Therapeutics to Host Q2 Fiscal 2023 Financial Results Conference Call

/CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), announces that it will release its Q2 Fiscal 2023 financial results on Thursday, August 10,...

HLS.TO : 3.44 (-1.43%)
Stocks in play: HLS Therapeutics Inc.

Announces today that John Hanna has been appointed to the Board of Directors, while Greg Gubitz, Chair ...

HLS.TO : 3.44 (-1.43%)
HLS Therapeutics Announces Updates to its Board of Directors

/CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS) announces today that Mr. John Hanna has been appointed to the Board of Directors (the...

HLS.TO : 3.44 (-1.43%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Key Turning Points

3rd Resistance Point 3.67
2nd Resistance Point 3.63
1st Resistance Point 3.53
Last Price 3.44
1st Support Level 3.39
2nd Support Level 3.35
3rd Support Level 3.25

See More

52-Week High 11.22
Fibonacci 61.8% 8.21
Fibonacci 50% 7.28
Fibonacci 38.2% 6.35
Last Price 3.44
52-Week Low 3.34

See More

Business Summary

HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company products include Clozaril, Vascepa, Trinomia, and Perseris. The company earns revenue in the form of product...

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar